A Phase 2 Safety and Efficacy Study of Filgotinib and GS-9876 in Cutaneous Lupus Erythematosus

The purpose of this randomized, double blind, placebo-controlled study is to evaluate the safety and efficacy of filgotinib and GS-9876 in participants with active Cutaneous Lupus Erythematosus. The trial is sponsored by Gilead Sciences, Inc.

To Learn More Contact
GS-US-436-4092@gilead.com
ClinicalTrials.gov identifier: NCT03134222

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up